DYRK2 and neoplasm: Although the expression of some molecules can reduce the proliferation of tumor cells, the production of CAM-DR is consistent with the clinical practice that is not sensitive to the treatment of inert lymphomas, such as DYRK2 (Wang et al., 2015).